Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge

Nose, T; Funakoshi, Y; Suto, H; Nagatani, Y; Imamura, Y; Toyoda, M; Kiyota, N; Minami, H

Funakoshi, Y (通讯作者)，Kobe Univ, Hosp & Grad Sch Med, Dept Med, Div Med Oncol Hematol, 7-5-1 Kusunoki Cho,Chuo Ku, Kobe, Hyogo 6500017, Japan.

MOLECULAR AND CLINICAL ONCOLOGY, 2022; 16 (5):

Abstract

Although nivolumab is administered every two or four weeks, high programmed cell death-1 (PD-1) binding of nivolumab on T cells lasting for several mo......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索